CD80 and B-cell non-Hodgkin lymphoma: Moreover, the expression of CD80/CD86, in contrast to solid malignancies, is frequently observed in tumor cells from hematological malignancies (such as B cell lymphoma) [45] raising the possibility that the crosstalk between the B7 ligand family and the CD28 receptor superfamily may be further complicated in hematological malignancies.